Building on our achievements of treating haemophilia with inhibitors, we aim to be a trusted leader in haemophilia. Novo Nordisk has an industry-leading pipeline portfolio, addressing the many faces of haemophilia and with the potential to innovate the treatment options.
We recognise however that the medical products are only part of the response to haemophilia and our broader commitment to the haemophilia community is vital to realising our ambitions.
To make our vision a reality, and improve outcomes for all people with haemophilia, three core ambitions need to be realised.
Strengthen understanding of haemophilia in the broader society
Working with representatives from across the haemophilia community we are continuously strengthening understanding. This has recently resulted in a new initiative launched in 2010. This largest multi-country psychosocial survey conducted to date in haemophilia, HERO (Haemophilia Experiences, Results and Opportunities) will provide new evidence of what it is like to live with haemophilia. Novo Nordisk is furthermore also an active partner on World Haemophilia Day.
Improve access to diagnosis, care and treatment
We work to improve access to diagnosis, care and treatment primarily through our commitment to the Novo Nordisk Haemophilia Foundation, established in 2005, focusing on capacity building, awareness creation as well as improving diagnosis and registries. The Foundation has an impact around the world supporting healthcare professionals and reaching out to people with haemophilia and allied bleeding disorders, their family members and other community members.
Advance treatment and care through innovation
Finally, we collaborate with patient and medical organisations around the world to advance treatment and care through innovation supporting education and advocacy and the development of new thinking. As an example, our Access to Insight programme supports global haemostasis research with grants, scholarships and awards.